Biotronik Recordkeeping, Sponsor Oversight Lapses Lead To Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
Biotronik maintains it provided FDA with requested copies of clinical data during a recent inspection, rendering a 1June 4 warning letter to the firm unnecessary
You may also be interested in...
Sponsor Monitoring Practices, Inspection Readiness Criticized By FDA Reps
FDA is considering changing its approach to foreign audits to address situations where agency inspectors felt they had insufficient time to complete inspections
Biotronik Neglects To Report “Dear Doctor” Notice, Draws FDA Warning Letter
Implantable cardioverter defibrillator firm Biotronik plans to wrap up a recall of Belos VR andBelosVR-T ICDs within the next month, according to company reps
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.